At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 46 enrolled
Drug / intervention
Benralizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Multi-Centre Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics
In Brief
A Phase 3 clinical trial evaluating Benralizumab and Placebo for Asthma. Completed, enrolled 46 participants across 6 sites.
Detailed Summary
This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks on allergen-induced inflammation in subjects with mild atopic asthma challenged with an inhaled allergen.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesCanada
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 2016
Enrollment StartOct 2016
Primary CompletionOct 2019
TodayJul 2026
First PostedJul 1, 2016
Enrollment StartOct 11, 2016
Primary CompletionOct 22, 2019
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 10.0 years ago
Interventions
Benralizumabbiological
Benralizumab subcutaneously on study day 0 until study week 16 day 1 inclusive
Placeboother
Placebo subcutaneously on study week 0 until study week 16 day 1 inclusive